Patents by Inventor Edward J. Merino

Edward J. Merino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Small molecule prolactin receptor inhibitors, pharmaceutical compositions and treatment methods using such inhibitors
    Patent number: 11834423
    Abstract: Small molecule inhibitors (SMIs) of the Prolactin receptor, pharmaceutical compositions of the SMIs, and methods for treating patients suffering from disorders characterized increased expression or excitation of the Prolactin receptor, including breast cancer, prostate cancer and nociceptive pain disorders such as migraine headache, by administering pharmaceutical compositions of SMIs are provided.
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: December 5, 2023
    Assignees: University of Cincinnati, University of Texas System, The Hebrew University of Jerusalem
    Inventors: Nira Ben-Jonathan, Eric R. Hugo, Edward J. Merino, Abraham J. Domb, Armen N. Akopian
  • Small Molecule Prolactin Receptor Inhibitors, Pharmaceutical Compositions and Treatment Methods Using Such Inhibitors
    Publication number: 20220024881
    Abstract: Small molecule inhibitors (SMIs) of the Prolactin receptor, pharmaceutical compositions of the SMIs, and methods for treating patients suffering from disorders characterized increased expression or excitation of the Prolactin receptor, including breast cancer, prostate cancer and nociceptive pain disorders such as migraine headache, by administering pharmaceutical compositions of SMIs are provided.
    Type: Application
    Filed: September 30, 2021
    Publication date: January 27, 2022
    Inventors: Nira Ben-Jonathan, Eric R. Hugo, Edward J. Merino, Abraham J. Domb, Armen N. Akopian
  • Small molecule prolactin receptor inhibitors, pharmaceutical compositions and treatment methods using such inhibitors
    Patent number: 11168061
    Abstract: Small molecule inhibitors (SMIs) of the Prolactin receptor, pharmaceutical compositions of the SMIs, and methods for treating patients suffering from disorders characterized increased expression or excitation of the Prolactin receptor, including breast cancer, prostate cancer and nociceptive pain disorders such as migraine headache, by administering pharmaceutical compositions of SMIs are provided.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: November 9, 2021
    Assignees: University of Cincinnati, University of Texas System, The Hebrew University of Jerusalem
    Inventors: Nira Ben-Jonathan, Eric R. Hugo, Edward J. Merino, Abraham J. Domb, Armen N. Akopian
  • Small Molecule Prolactin Receptor Inhibitors, Pharmaceutical Compositions and Treatment Methods Using Such Inhibitors
    Publication number: 20190202794
    Abstract: Small molecule inhibitors (SMIs) of the Prolactin receptor, pharmaceutical compositions of the SMIs, and methods for treating patients suffering from disorders characterized increased expression or excitation of the Prolactin receptor, including breast cancer, prostate cancer and nociceptive pain disorders such as migraine headache, by administering pharmaceutical compositions of SMIs are provided.
    Type: Application
    Filed: September 8, 2017
    Publication date: July 4, 2019
    Inventors: Nira Ben-Jonathan, Eric R. Hugo, Edward J. Merino, Abraham J. Domb, Armen N. Akopian
  • Hydrogen peroxide-activated compounds as selective anti-cancer therapeutics
    Patent number: 10071954
    Abstract: Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of hydrogen peroxide and are therefore selective anti-cancer therapeutics for cancers associated with elevated reactive oxygen species (ROS). Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: September 11, 2018
    Assignee: University of Cincinnati
    Inventors: Edward J. Merino, James Mulloy, Anish K. Vadukoot, Mark Wunderlich, Safnas F. Abdulsalam
  • Hydrogen Peroxide-Activated Compounds as Selective Anti-Cancer Therapeutics
    Publication number: 20160318849
    Abstract: Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of hydrogen peroxide and are therefore selective anti-cancer therapeutics for cancers associated with elevated reactive oxygen species (ROS). Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.
    Type: Application
    Filed: October 2, 2015
    Publication date: November 3, 2016
    Inventors: Edward J. Merino, James Mulloy, Anish K. Vadukoot, Mark Wunderlich, Safnas F. Abdulsalam
  • ROS-activated compounds as selective anti-cancer therapeutics
    Patent number: 9394233
    Abstract: Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elevated ROS. Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: July 19, 2016
    Assignees: Cincinnati Children's Hospital Medical Center, University of Cincinnati
    Inventors: Edward J. Merino, James C. Mulloy, Guorui Li, Tiffany Bell-Horwath
  • pH AND LIGHT ACTIVATED ANTI-CANCER DRUGS
    Publication number: 20160101177
    Abstract: Described are compositions of metal complexes that can be selectively activated by light when the metal complex is under acidic conditions, such as in a cancer cell. In some aspects, the metal complex can be utilized in a drug formulation with anti-cancer activity.
    Type: Application
    Filed: October 14, 2015
    Publication date: April 14, 2016
    Inventors: Elizabeth T. Papish, Jared J. Paul, Edward J. Merino
  • ROS-Activated Compounds as Selective Anti-Cancer Therapeutics
    Publication number: 20130230542
    Abstract: Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elevated ROS. Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 5, 2013
    Applicants: CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI
    Inventors: Edward J. Merino, James C. Mulloy, Guorui Li, Tiffany Bell-Horwath